Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral Viread

April 26, 2004

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Foster City, Calif.-based Gilead Sciences on Thursday announced first-quarter 2004 net profits of $114.4 million, up from a net loss of $438.1 million during the same quarter last year, an increase largely driven by sales of its antiretroviral drug Viread, Reuters reports (Berkrot/Pierson, Reuters, 4/22). Gilead -- which manufactures Viread, the fifth best-selling antiretroviral drug in the United States -- in July 2003 launched a second antiretroviral drug, Emtriva, and is developing a once-daily combination pill to compete with industry leader GlaxoSmithKline's top-selling Combivir (Kaiser Daily HIV/AIDS Report, 10/30/03). Sales of Viread increased 80% to $193.1 million during the first quarter of 2004, and the company raised its yearly sales forecast for the drug to between $725 million and $775 million. In addition, sales of Emtriva reached $12 million in the first quarter. The company also said it plans to start clinical trials of a new protease inhibitor, according to Reuters (Reuters, 4/22).

Back to other news for April 26, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on Tenofovir (Viread)

Tools
 

Advertisement